Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSC | P53634 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 9/20 | 0.38 |
| ▸ | CTSK | P43235 | 8/20 | 0.38 |
| ▸ | CTSB | P07858 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880884 | 0.92 | CTSL (0.38) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL26139097 | 0.82 | CTSL (0.38) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL22826896 | 0.81 | CTSL (0.42) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL2106914 | 0.79 | CTSC (0.42) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL19169463 | 0.78 | CTSL (0.40) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL17447542 | 0.78 | CTSS (0.41) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL11256614 | 0.76 | CTSL (0.38) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL17447512 | 0.76 | CTSL (0.39) | CTSLCTSCCTSSCTSKCTSB | |
| SCHEMBL13435738 | 0.76 | — | — | |
| SCHEMBL2394821 | 0.75 | CTSL (0.59) | CTSLCTSCCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11541044-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-03 | — | — | US | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-10857140-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-9856279-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541044-B2 | K-Ras modulators | KRAS, HRAS, NRAS | CTSL 2579/4885CTSC 2239/4885CTSS 985/4885 |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CTSL 2731/4885CTSC 2885/4885CTSS 1024/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-10857140-B2 | K-Ras modulators | KRAS, HRAS, NRAS | CTSL 3326/4885CTSC 2934/4885CTSS 1537/4885 |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | AR, LHCGR, FSHR | CTSL 3973/4885CTSC 1495/4885CTSS 3806/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | CTSL 4858/4885CTSC 3073/4885CTSS 4568/4885 |
| US-20230002362-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK3, JAK2 | CTSL 2477/4885CTSC 1002/4885CTSS 1878/4885 |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, TP53, MCL1 | CTSL 65/4885CTSC 224/4885CTSS 45/4885 |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CTSL 3473/4885CTSC 3314/4885CTSS 559/4885 |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | CTSL 217/4885CTSC 843/4885CTSS 166/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | CTSL 3071/4885CTSC 1540/4885CTSS 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.